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ABSTRACT AND KEYWORDS 
TITLE: CORRELATION BETWEEN SARCOPENIA AND VITAMIN D LEVEL IN 
ELDERLY POPULATION 
AUTHOR: PROF.S.SIVAKUMAR, DR.S.PRABHAGARAN 
DEPART. OF GERIATRIC MEDICINE, MADRAS MEDICAL COLLEGE 
BACKGROUND: 
Sarcopenia is defined as progressive reduction in musclemass, muscle strength and 
function that affects older people.Muscle mass decrease is probably the single most 
frequent cause of late-lifedisability among older people. It is directly responsible for 
functional impairment with lossof strength, and increased likelihood of falls and 
fractures.Many studies have shown that low serum 25(OH)D levels are related to 
accelerated losses in muscle mass and reduced muscular strength, reduced muscle 
power and gait speed. In this study relation between vitamin D level and sarcopenia 
was analyzed. 
METHODS: 
50 elderly patient of age more than 65years without sarcopenia and 50 elderly with 
sarcopenia in Geriatric department were selected. Elderly with sarcopeniawere 
selected based on EWGSOP definition using muscle mass, strength and gait 
speed.The vitamin D level of both the group were compared. 
RESULTS: 
Prevalence of vitamin Ddeficiency(includes both deficiency and insufficiency)  in both 
group were 78% and 86% respectively. Mean Vitamin D levelin both groups were 
41.03nmol and 58.69nmol respectively. Severe deficiency with vitamin D less than 
25nmol was seen in 12% and 6% in sarcopenic and non sarcopenic elders 
respectively. 
CONCLUSION 
Vitamin D deficiency is one of the contributing factors for sarcopenia and the 
prevalence rates for severe vitamin D deficiency is higher in sarcopenic elderly 
KEYWORDS 
 Sarcopenia Vitamin D, Deficiency 
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INTRODUCTION 
 Musculoskeletal system is one of the important organ system in the 
human body. The disease and disorder ofmusculo skeleton are common in 
late life and have a major influence on function and quality of life. There are 
many disease that affect the musculo skeleton and are forms of myopathy. 
 The disease or condition that cause loss of skeletal muscle mass is 
called sarcopenia. The wordSarcopenia derives from the Greek and 
means“poverty of flesh.”In medical terms, sarcopenia is defined as a 
nonspecific and can be caused by aging, wasting, disuse, illness, or starvation 
or can also a secondary consequence of neuropathy or ischemia.Sarcopenia is 
more common in older populations. There are multiple contributing factor for 
sarcopenia that includes, early life developmental influences, the ageing 
process over the life course, less than optimal diet, sedentary lifestyle style or 
bed rest, chronic illness, certain drug treatments and hormonal influence. 
Sarcopenia represents an impaired state of health with many adverse 
outcomes that includes 
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Vitamin D, which is a fat soluble vitamin and a major steroid hormone 
has a   major role in bone and calcium metabolism. Apart from this function, 
it also plays a major role in cell growth regulation, bone formation, 
strengthening of skeletal muscle, regulation immune system, muscle strength, 
hair growth, immunity against infection, reducing the risk of autoimmune 
diseases, role in systemic hypertension and diabetes mellitus. 
 Some of the morphological changes in musculo skeletal system was 
associated with vitamin D deficiency. For example, patients with 
osteomalacia with muscle dysfunction associated with vitamin D deficiency 
show degenerative changes such as fat infiltration in muscle fibres, opaque 
fibers, ghostlike necrotic muscle fibers, regenerating andfibrosed muscle, 
enlarged interfibrillar spaces, fibrosis, glycogen granules, andatropy of the 
type II muscle fiber. As is the case with vitamin D-deficient patients, it is 
well known that elderly people show aberrant muscle morphology.  Many 
recent studies shows that vitamin D deficiency as one of the contributing 
factor for progression of sarcopenia. Also many interventional study showed 
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a significant improvement in muscle strength by vitamin D supplementation 
in elderly population. Vitamin D deficiency is more prevalent in elderly. 
Older individual with poor dietary intake, chronic bedridden, stays indoor 
will have subclinical vitamin D deficiency. Vitamin D deficiency in older 
people is thought to occur mainly due to decreased exposure to sunlight, poor 
dietary intake of vitamin D, and reduced skin capacity of the skin to synthesis 
vitamin D. 
 However there are no Indian studies on correlation between sarcopenia 
and Vitamin D level. Hence an attempt to assess the correlation between 
vitamin D level and sarcopeniawas done in this study. 
  
  
 
 
AIM OF THE STUDY 
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    AIM OF THE STUDY 
1. To assess the correlation between sarcopenia and Vitamin D level in the 
elderly population. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 Practice of Geriatric medicine mainly focus on older population who 
are frail, as they are thought to be the population at highest risk for various 
adverse outcomes [1] Although in elderly the physiological ageing changes 
may be the foundation of frailt , the phenotype of frailty initially present as 
loss of weight or loss of muscle mass (sarcopenia)  even before the 
establishment of adverse outcomes. This results in weakness of muscles, 
decreased exercise tolerance or endurance, low physical performance and 
slowed task performance (such as gait speed)[2–4]  
 
PHYSIOLOGY OF SKELETAL MUSCLE: 
 All skeletal muscle are enclosed by a sheath of connective tissue called 
epimysium. Bundles of muscle fibers and individual contracting units of 
muscle fibers are surrounded by partitions of the connective tissue 
constituting the perimysium and the endomysium, respectively. Blood 
vessels, lymphatics, and nerves reach all the muscle compartments by way of 
these fibrous partitions. Matured single muscle fibers are long multinucleated 
and cylindric units separated from other cells and a membrane surrounding 
this unit, the sarcolemma.  Skeletal muscle fibres contain myofibrils which is 
made up of the contractile proteins myosin, actin, tropomyosin, and troponin 
and the structural supportive proteins actinin and titin. The particular spatial 
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arrangement of the thick and thin contractile proteins is responsible for the 
characteristic cross-striations in skeletal muscle.[5] 
 
MOTOR UNIT: 
 Lower spinal cord motor neurons provide a common pathway for 
transmitting neural impulses from upper motor levels of the central nervous 
system to the skeletal muscle. This information is directed to skeletal muscles 
via the ventral roots, peripheral nerves, and cranial nerves. Within the single 
muscle the muscle fibers are innervated by motor neurons and these motor 
neurons are grouped in the spinal cord as it innervates the single muscle. This 
forming the motor neuron pool for that muscle. The activation of a motor 
neuron brings all the muscle fibers to the mechanical threshold, therefore, a 
single motor neuron and its associated muscle fibers constitute the motor unit 
that is the smallest that can be activated to induce movement. On the basis of 
the speed of contraction, three types of motor units can be distinguished: 
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 These differences in motor unit performance are based on physiologic 
and biochemical characteristics of their constituent muscle fibers.[6] 
CONTRACTION: 
 The raised intracellular calcium concentration is the vital event in 
muscle contraction which occurs due to the transduction changes in 
sarcolemma. Muscle relaxes as a result of calcium pumping back to the SR, 
release of calcium from troponin, and cessation of interaction between actin 
and myosin filaments. 
NEURAL:  
 Several factors regulate muscle contractions, including innervations of 
muscle fibers. Muscle fibres innervation state alteration leads to change in the 
expression of gene which transcript protein involved in the excitation – 
contraction coupling. This variation in expression leads to excitation – 
contraction coupling difference. During development, the spinal motor 
neuron innervates the muscle fibers. This various subpopulation of motor 
neuron determines the fiber type by activating the contraction at various rates 
Fiber type is determined by interaction with different subpopulations of these 
motor neurons that activate contraction at different rates, ranging from 10 Hz 
(slow twitch) to 100 Hz (fast twitch fatigue resistant) or 150 Hz (fast twitch 
fatigue sensitive). Depolarization of myotubes in culture stimulates the 
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appearance of DHPR (dihydropyridine) binding sites, suggesting that DHPR 
expression was induced by the induction of muscle activity during 
innervation[7,8] 
AGEING AND MUSCLE: 
 40–50% of the human body was mainly comprised of skeletal muscle 
and the skeletal muscle is composed of muscle tissue, connective tissue, 
blood vessels and nerves. Bundle of muscle fibers formed from the fusion of 
precursor cells called Myoblasts. The muscle fibers is of two types namely 
 
Type II muscle fiber consists of two components: 
 
  The normal ageing process shifts the type of fibre towards TypeI 
muscle fibre.[11]. Muscle contraction is of various types  
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 The adaptive response of the skeletal muscles is to protect themselves 
from the damage caused by ROS – reactive oxygen species. Sarcopenia – the 
reduction in muscle mass with ageing that lead to decline in muscle strength 
and muscle power. After 50 years of age there will be decline in basal 
metabolic rate (BMR) by 4% per year. The myosin heavy chain production 
also reduces with age but the sarcoplasmic protein pool remains unchanged 
[12, 13]. The ability of the skeletal muscle to regenerate and hence the overall 
muscle mass decrease with age. The infiltration of fat into the muscle also 
increases with ageing. Many ageing changes occurs due to decline in physical 
activity. During ageing there will be loss of muscle fibres and motor neuron. 
The loss of muscle fibres is mainly due to the loss of motor neurons. The 
ageing muscle shows a decline in motor unit demonstrated by many 
electrophysiological studies[14]. With ageing, the size of the average motor 
unit increases with age. In some muscles, the limitation in the maximum 
force generated in older individual is not due to the failure of the central 
nervous system but it is mainly due to the decline in firing of the individual 
motor nerves at the time of maximal voluntary contraction [15]. The 
10 
 
fatigability of the muscleduring a sustained contraction is common in elderly 
compared to younger persons. Atropy of the ageing muscle fibre is more 
restricted towards type II muscle fibre this selectivity is more important for 
the muscle performance because the type II muscle fibre generate more 
power compared to type I especially in leg muscles. The relation between the 
rate of muscle contraction and muscle relaxation to the dysfunction in the 
calcium release is still not fully understood. Welleet al. study illustrate that 
aged muscle decreased expression of mRNA that encodes protein which 
plays role in ATP synthesis and miticondrial electron transport chain [16]. 
With the ageing process there will be more accumulation of DNA deletion in 
the miticondria of the skeletal muscle [17]. Thus during senescence the 
changes in the skeletal muscle affects muscle bulk, muscle performance and 
strength, endurance and function.   
 In the older individual, the loss of functional independence and the 
disability is contributed by the ageing changes of the skeletal muscle. Age-
related weakness may be associated with fatigue, weakness discerned as an 
absolute decrease in muscle force, and fatigue as a progressive decline in 
force with prolonged physical activity. Decreased in muscle strength is 
associated with decreased in ADL like climbing stairs, getting up from the 
chair that leds to loss of functional independence. 
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AGE RELATED CHANGE IN MUSCLE A SUMMARY: 
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FIG.1 AGEING DECLINE OF MUSCLE MASS AND STRENGTH 
 
CONTRIBUTION FOR WEAKNESS IN AGEING: 
NEUROGENIC FACTOR: 
Neurogenic mechanisms of decline in muscle function with age include 
reduction in the number and/or size of spinal cord motor neurons, alterations 
in axonal flow, and the neuromuscular junction. Each of these factors, 
individually or in combination, leads to chronic muscle denervation and 
motor unit remodeling and hence contribute to the weakness in ageing. 
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MYOGENIC FACTOR: 
Primary muscular or myogenic factors refer to a group of alterations 
including contraction-induced injury and alterations in muscle signal 
transduction (trophic factor/ hormone resistance). The phenomenon of 
contraction induced injury is related to increased mechanical frailty and 
decline in muscle restorative capacity with age. Also, older muscles recover 
more slowly and do not exhibit complete recovery when compared with those 
in younger population. Eccentric contraction injury has also been 
demonstrated in older individuals. Insulin and IGF-1 resistance in aging 
skeletal muscle have been reported that further contributes to the progression 
of sarcopenia. 
 
COMBINED FACTORS: 
 Combined mechanisms include muscle unloading and EC uncoupling. 
Muscle unloading associated with sedentary lifestyle is a major determinant 
of muscle atrophy in the elderly population. The decrease in physical activity 
is a combined process in which the lower the nerve activation, the lower the 
muscle contraction. This process leads subsequently to muscle atrophy. 
 Apart from nutritional, immobility, sedentary lifestyle, malnutrition 
and other contributing factor these neurogenic and myogenic factor of ageing 
 process further add up to the pathophysiological of sarcopenia. These f
increase the progression 
 Even though the ageing muscle contributes to the progression of 
decline in muscle strength there are many other contributing factor which 
further progress the sarcopenia.
FIG.2 VICIOUS CYCLE OF SARCOPENIA AND DISABILITY
14 
and worsening of sarcopenia. 
 
actor 
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SARCOPENIA: 
The capacity to live independently is essential for quality of life at all 
ages. With ageing this capacity is endangered by the degeneration seen in 
elderly overlying by co morbid illness. Decline in skeletal muscle strength 
and performance is one of the major determinant for functional independent 
apart from cognitive decline in elderly. In the past decade the annihilating 
effect of osteoporosis and dementia have been concentrated, but the 
sarcopenia that include decline in muscle strength and performance which is 
the cornerstone for fraility have not been focused. In 1989, Rosenberg 
[18]defined the term sarcopenia that refer to the age related loss of skeletal 
muscle mass and size. The word sarcopenia is formed from the greek word 
‘sarx’which means fleshand the word‘penia’ which means loss. Rosenberg’s 
principle for defining the term sarcopenia that encapsulated ageing decline in 
muscle mass as much importance has not been given that time. The 
phenomenon of loss of muscle strength and even muscle mass with ageing 
was observed years earlier in 1931 when Critchley [19] noted that muscle 
mass loss occurs with ageing  and the process of loss of certain fibre type in 
human skeletal muscle over time was observed in studies of muscle biopsies 
even after the first decade of life [20]. The decline in skeletal muscle with 
ageing was around 6% every decade which is showed by many longitudinal 
studies. The decline in muscle mass starts around 45 years of age. Therefore a 
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typical 85 year old person will have a muscle mass and size approximately 
three quarters of that when he or she was at 45 years of age. Even elderly 
population who are functionally independent, active and healthy are not 
immune to the sarcopenic process and it seems as though everyone loses 
muscle mass as they grow older [21]. Thus, as per Rosenberg’s definition the 
occurrence of sarcopenia in elderly population is 100%. With that being said 
there are appreciable difference from person to person in peak skeletal 
muscle mass. Because of these tremendous difference there is variation in the 
muscle mass value of various elderly. Some of the older adults have a muscle 
mass comparable to healthy young adult, whereas other have a muscle mass 
so low that their functional ability and capacity severely compromised. 
Though the concept of saropenia is barely more than 20 years old it has 
gained popularity in academic circles and clinical setting in the west.   
 Geriatric syndromes are due to the unknown interaction between 
disease and ageing changes that results in producing a constellation of signs 
and symptoms. Geriatric syndrome leads to involvement of multiple systems. 
Instability, falls and incontinence are some of the geriatric syndromes 
[22].We suggest Sarcopenia to be considered as a Geriatric syndrome 
because this will promote the treatment and management of sarcopenia[23 – 
24]. 
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DEFINITION: 
Sarcopenia is a syndrome characterised by progressive and generalised 
loss of skeletal muscle mass and strength with a risk of adverse outcomes 
such as physical disability, poor quality of life, increased morbidity, low 
functional independence and death [25, 26].           
 The European Working Group on Sarcopenia in Older People 
(EWGSOP) defined a clinical definition and diagnostic criterion for 
sarcopenia. 
 The EWGSOP included representatives from four participant 
organisations 
 
The EWGSOP recommends the use of both skeletal muscle mass and 
muscle function (strength or performance ) for the diagnosis of sarcopenia. 
The diagnosis of sarcopenia needs the presence of criteria 1 and the presence 
of either criteria 2 or 3. Diagnosis of severe sarcopenia is based on criterion 1 
plus criterion 2 plus criterion 3 [27]. 
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The report of European working group on sarcopenia in older people 
says that the principle in using 2 criteria i.e, lower skeletal muscle mass and 
muscle performance is that strength of the muscle does not depend mainly on 
skeletal muscle mass and the relationship between strength and mass is not a 
linear. The EWGSOP report also divided sarcopenia into three stage that 
reflects the severity of the condition. 
 
  The European society of parenteral and entral nutrition special 
interest groups effort 
characterized by loss of muscle mass and muscle strength. Although 
sarcopenia is primarily a disease of the older individual , its development 
may be associated with condition that are not exclusively seen in older 
person, like disuse, malnutrition and cachexia. Like osteopenia, it can also be 
seen in younger patients suc
muscle mass and muscle strength caused by such condition is usually 
functionally less relevant in younger individual, as their muscle mass and 
muscle strength is higher before it is affected by these condit
 The international working group on sarcopenia
are “sarcopenia is defined as the age associated loss of skeletal muscle mass 
and function. The cause of sarcopenia was multi factorial and can include 
disuse, insulin resistance and nu
component of sarcopenia, the two condition are not the same” 
19 
defines sarcopenia as “sarcopenia is a condition 
h as those with inflammatory disease. The loss of 
ion”
 consensus wordings 
tritional deficiency. While cachexia may be a 
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 The society of Sarcopenia, Cachexia and wasting disorders defines 
“sarcopenia, that is reduced muscle mass with limited mobility, should be 
considered an important clinical entity and defined as a condition with 
muscle loss and reduced gait speed”. 
PREVALENCE OF SARCOPENIA: 
The occurence of sarcopenia showed in various research study varies 
considerably. This shows the difference in the elderly population studied, 
different method used to measure muscle mass and size and difference in the 
normal study group that were used to derive the sarcopenia threshold. Within 
the existing literature, the prevalence of sarcopenia in 60 – 70 years old is in 
the order of 5% to 13% [28]. These prevalence estimates increase to 11% to 
50% for the population aged 8o years or older. Some reference estimated 
approximately 15% of people aged 60 to 69 years and approximately 40% of 
people older than 80 years [9]. The world health organization(WHO) suggest 
that there were 600 million people aged 60 or older in the year 2000 and that 
the number will increase to 1.2 billion by the year 2025 [29]. WHO count 
suggest that sarcopenia affects more than 50 million population today and it 
will affect more than 200 million population over next 40 years. 
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PATHOPHYSIOLOGY: 
 Sarcopenia has been contributed by many factors that include normal 
ageing changes, malnutrition, lack of physical activity, bed rest, chronic 
illness, smoking and certain drug therapy [30–32]. 
 The pathogenesis involved are protein synthesis, protein degradation, 
integrity of the neurological and muscular system and contents fat in muscles.  
 
FIG.3 PATHOPHYSIOLOGY OF SARCOPENIA 
  The progression and development of sarcopenia was contributed by 
many factors. These risk factors are categorized as
FIG.4 CONTRIBUTING FACTOR FORSARCOPENIA
Many mechanism attribute to the process of
contribution varies for every individual.
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Sarcopenia the 
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The mechanism of sarcopenia is a complex process due to the ageing 
changes in musculoskeletal system in its structure as well as performance 
[33].The contributing and risk factors include sedentary life style, smoking, 
malnutrition, inadequate intake, obesity, ageing hormonal changes, neural 
changes and metabolic factor. Genetic factors also play a role insarcopenia.  
 
 The etiology of sarcopenia have beendivided into “intrinsic” and 
“extrinsic” factors. Reduced in anabolic hormonal level (DHEA, Estrogens, 
Growth hormones, IGF-1), increase in apoptosis of muscle fibers, increases 
of inflammatory cytokines (e.g. TNF-α, IL-6), free radical injury, 
mitochondrial dysfunction in muscles and a decrease in the number of α-
moto neurons are the intrinsic factors. Decreased intake of protein and 
essential amino acids, low level of vitamin D, acute and chronic illness and 
sedentary life style are the extrinsic actors leads to sarcopenia. 
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FIG.5 PHYSIOLOGY OF SARCOPENIA 
 
The development of sarcopeniai.e, deline in muscle mass and strength 
due to mismatch between loss and renewal of muscle protein. The imbalance 
between atrophy or apoptosis and hypertrophy and satellite cell production. 
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SARCOPENIC OBESITY: 
In conditions such as malignancy, rheumatoid arthritis and ageing, lean 
body mass is lost while fat mass may be preserved or even increased [34]. 
This state is called sarcopenic obesity, and thus the relationship between  
age-related reduction of muscle mass and strength is often independent of 
body mass. It had long been thought that age-related loss of weight, along 
with loss of muscle mass, was largely responsible for muscle weakness in 
older people [35]. However, it is now clear that changes in muscle 
composition are also important, e.g.‘marbling’, or fat infiltration into muscle, 
lowers muscle quality and work performance [36]. While weight changes 
vary widely between individuals, certain patterns of age-related change in 
body composition have been observed. In ageing men, the percentage of fat 
mass increases initially, then levels oﬀ or decreases. Such change has been 
attributed to an accelerated decrease in lean mass, along with an initial 
increase and a later decrease in fat mass [37]. Women show a generally 
similar pattern [37]. Intramuscular and visceral fat increase with ageing while 
subcutaneous fat declines [38,39]. 
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ASSESMENT TECHNIQUE FOR SARCOPENIA: 
MUSCLE MASS: 
 A variety of method has been used for the assessment of skeletal 
muscle mass [40].The elements that determine the assessment method as a 
suitable one for clinical and research purpose are 
 
Body imaging techniques.  
The estimation of skeletal muscle mass and lean body mass done by 
three imaging technique  
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Computed tomography and Magnetic resonance imaging can 
differentiate fat tissue other soft tissues hence consider as gold standard 
technique for the purpose of research. Because of the cost, ease to access and 
radiation risk these imaging technique is not used as a routine method in 
research and clinical study [41].dual energy X ray absorptiometry  is the 
alternative method both for research and clinical practice use to differentiate 
fat mass, bone and lean  body mass. 
 
Bioimpedance analysis. 
 Bioimpedance analysis (BIA) evaluates fat volume, skeletal muscle 
mass and lean body mass. The advantage of technique over the other are 
inexpensive, easy to assess, reproducibility and suited or both the ambulatory 
and bedridden elderly population. 
 In standard conditions, the acceptability of the technique was studied 
for more than ten years[35], and bio impedance analysis results under 
standard conditions has been correlated well with Magnetic Resonance 
Imaging predictions [43]. Prediction equations have been validated for 
multiethnic adults and reference values established for adult white men and 
women, including older subjects [44–46].Thus, Bio Impedance Analysis is a 
good alternative to Dual energy xrayabsorpsiometry. 
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Total or partial body potassium per fat-free soft tissue. 
As skeletal muscle contains more than fifty percent of the total body 
potassium (TBK) pool, thus total potassium pool is a best methodfor skeletal 
muscle estimation. Many recent studies have proposed the use of partial body 
potassium (PBK) of the arm as a better alternative [47]. PBK of the arm is 
safe and inexpensive. Though the total body potassium pool is the best 
method for skeletal mass estimation, this method is not used in clinical 
practice. 
 
Anthropometric measures.  
 Mid upper arm circumference and skin fold thickness can used for 
estimation of skeletal muscle mass. Measurement of Calf circumference 
correlates positively with muscle mass. The measure of calf circumference 
less than 31 cm has been linked with the occurrence of disability [48]. As the 
calf circumference, mid upper arm circumference and skin fold thickness are 
not reliable for the measurement of sarcopenia they are not used in routine 
clinical practice. 
 
MUSCLE STRENGTH: 
 The techniques validated for the estimation of muscle strength includes 
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The relevant method for the assessment of gait and physical function is 
the use of lower limb than upper limb. Although lower limbs are more 
relevant the widely used method has been hand grip strength. The cost, 
availability and ease of useare the elements that determine the assessment 
method as a suitable one for clinical and research purpose. 
 
Handgrip strength. 
Isometric hand grip strength is associated with 
 
The mobility problems and its clinical outcomes is better assessed by 
the hand grip strength than the skeletal muscle mass. Handgrip strength is a 
best simple method for the estimation of muscle strength, and also it 
correlates with leg strength. 
  
30 
 
Knee flexion/extension. 
Muscle strength represents the amount of force generated and muscle 
power represents the rate of work. In healthy elderly the muscle power i.e, 
the rate of work done by the muscle lost faster than the muscle strength. Both 
muscle power and muscle strength are vital for the performance, but muscle 
power is a best determinant of certain functional activities [50 - 52]. Both the 
isometric muscle strength and isokinetic muscle strength measurementscan 
made using modern commercial isokinetic dynamometers. Knee flexion 
techniques need special equipment so it is not feasible in clinical practice 
only suitable for research studies. 
 
Peak expiratory flow. 
 Peak expiratory flow (PEF) is determined by the strength of respiratory 
muscles in people without lung disorders. PEF is a cheap, simple and widely 
accessible technique which has prognostic value [53] even though it is not an 
recommended single measure. 
 
PHYSICAL PERFORMANCE: 
The various test used for the assessment of muscle performance 
includes, 
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Short Physical Performance Battery.  
The Short Physical Performance Battery includes variety of test 
evaluation of balance, gait speed, muscle strength and endurance. The SPPB 
includes the following test 1) ability to stand side by side with feet together 
2) ability to stand in semi tandem posture 3) ability to stand in tandem 
position 4) eight feet walking test 5) chair stand test for 5 times. The Short 
Physical Performance Battery, a comprehensive measure of physical 
performance used both in the clinical practice and research. 
Gait speed: 
Gait speed is a reliable method for the assessment of physical 
performance. Even though gait speed is part of the Short Physical 
Performance Battery it can also be used as a single parameter for research 
and clinical practice. 
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Timed get-up-and-go test: 
 Intimed get-up-and-go test (TGUG) the subjects was required to sit in a 
distance of 3meter and then ask to get up walk for the distance, turn around 
come back and sit in the chair. The time taken for this series of task was 
calculated. It assess both balance and gait. Balance function is assessed and 
scored in a five point scale. The Timed get up and go test, used in 
comprehensive geriatric assessment scale, and used for performance 
measurement. 
 
Stair climb power test.  
 The leg muscle power, strength and impairment can be measured 
clinically by the stair climb power test (SCPT). The Stair climb power test 
isuseful in some clinical research. 
 
  
 
CUTOFF POINTS: 
 Cut-oﬀ points depend upon the measurement technique chosen an
the availability of reference studies. EWGSOP recommends use of normative 
(healthy young adult) rather than other predictive reference populations, with 
cut-oﬀ points at two standard deviations below the mean reference value.
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d on 
 
 MUSCLE MASS: 
Baumgartner et al.
the muscle mass of all the four limbs using Dual energy x ray absorpsiometry 
as appendicular skeletal mass which is divided by height2. Skeletal Muscle 
Index = ASM/h2 (kg/m2)
below the mean Skeletal 
reference groups was defined as the
sarcopenia[66]. This method depends upon a measurement of appendicular 
skeletal muscle mass by DXA or estimation by BIA
calculated as skeletal muscle mass/height2.
skeletal muscle mass for the calculation of SMI. EWGSOP recommends both 
or the evaluation of muscle mass.
MUSCLE STRENGTH:
34 
 calculated the Skeletal muscle index by summing 
. A Skeletal Muscle Index 2 standard deviations 
Muscle Index of healthy young male and female 
 gender specific cut
. SMI can also be 
 NHANES study 
  
 
 off point for 
used absolute 
 
 Muscle strength measured based on hand grip strength using hand held 
Dynamometer based on BMI can be a surrogate marker for muscle strength. 
Hand Dynamometer is a very 
method to measure muscle strength. 
 
 
GAIT SPEED: 
 The EWGSOP has suggested algorithm based on gait speed 
measurement as the easiest and most 
 
GAIT SPEED: 
Gait speed can be used for 
off point of more than 
recommends gait speed as the initial test for the screening of 
 
35 
simplest method and a acceptable, reproducible 
 
reliable way to begin sarcopenia
case finding or screening in practice. A cut
0.8 m/s identifies risk for sarcopenia [54
sarcopenia. 
 
 
-
]. EWGSOP 
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EFFECTS OF SARCOPENIA: 
 In the year 2000, 35 million were in the age group of 65 years and it 
was increased to forty million in the year 2010, a increase of fifteen percent 
was noted. This population may further increase to fifty five million by the 
year 2020, a raise of 36% for that decade. By the year 2030, there will be 
about 72.1 million elderly population, about double compared to the 
population at 2008[55]. 
 In 2000, 1.5 million elderly population were hospitalized, and 33% 
which represents one third of the institutionalized population were admitted 
to longterm health care facilities due to their inability in performing 
ADL[56].Sarcopenia, the decline in muscle mass and muscle performance is 
thought to affect thirty percent of population over the age of 60 years and 
more than fifty percent of population over 80 years of age [57]. 
 Recent analysis shows that nearly 45% of elderly population in United 
states is affected by the sarcopenia. This corresponds to 18 million population 
in the year 2010 it was still continue to rise [58]. 
 In the U.S. population around 20% of elderly population were 
functionally disabled [59].The risk of disability is 1.5 to 4.6 times higher in 
elderly with sarcopenia compared to elderly with normal muscle mass and 
strength [60]. 
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 The fall risk will raise in the population associated with sarcopenia. 
Nearly half of accidental deaths in the population of age above 65 are related 
to falls. Though nutritional supplement, diet and exercise can reduce the rate 
of muscle mass and strength loss, even healthy and ambulant elderly will 
experience decline in muscle function [61]. 
 
COST OF SARCOPENIA: 
 The estimated direct healthcare cost attributable to sarcopenia in the 
United States in 2000 was $18.5 billion ($10.8 billion in men, $7.7 billion in 
women), which represented about 1.5% of total healthcare expenditures for 
that year. [60] 
 Healthcare expenditures due to sarcopenia cost roughly $900 per 
person per year [62]. People with chronic illnesses and activity limitations 
caused by conditions like sarcopenia have more physician visits and fill more 
prescriptions than those individuals with no activity limitations, all of which 
presents a greater burden on our health care system. These individuals also 
have more health visits [63]. 
 The United States spends more than $26 billion annually on additional 
health care costs for people over 65 who lose their ability to live 
independently over the course of a single year [64]. A 10% reduction in the 
sarcopenic population would save $1.1 billion. Though sarcopenia 
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contributes to numerous other health problems and accounts for a similar 
percentage of healthcare costs as osteoporosis, no public health campaigns 
are directly aimed at reducing the prevalence of sarcopenia.[60]  
 Thusby maintaining the functional independence and physical function 
in elderly population will preserve the good quality of life and also save 
health care cost of our country too. 
 
ASSESMENT OF SARCOPENIA: 
EWGSOP recommended an algorithm for screening of sarcopenia. It 
can to be done all person aged above 65 years and also in adults with risk of 
sarcopenia. 
 
FIG.6 ALGORITHM FOR ASSESMENT OF SARCOPENIA 
39 
 
VITAMIN D 
Lipid soluble vitamin apolar hydrophobic molecule which are all 
isoprene derivatives, they generally cannot be synthesized by the body in 
adequate amount and therefore must be supplied in the diet. They efficiently 
absorbed with the fat dietand once absorbed bound to lipoprotein or specific 
binding protein and transported to the specific organ. The important fat 
soluble vitamins are vitamin A, B, C, D, E and K. Vitamin D is a steroid pro 
hormone. It is synthesised from steroid that occurs in animal, plant and yeast 
which undergo many metabolic changes inside the human body and give rise 
to a hormone called as calcitriol which play a major role in calcium and other 
metabolic action.  
 Vitamin D, is lipid soluble vitamin and an important nutrient in our 
body. 1,25dihydroxycholecalciferol [1,25(OH)2D] is the major steroid 
hormone in our body. It is involved in mineral ion homeostasis regulation 
primarily. Vitamin D and its metabolites are mainly hormones and hormone 
precursors rather than to be called as vitamins, as 1,25(OH)2D  is synthesized 
endogenously. UV rays acts on the skin and causes 7-dehydrocholesterol to 
cleave by a photochemical reaction and results in Vitamin D. If melanin 
content is more in skin the production of Vitamin D by skin is reduced. 
Similarly sunscreens having high SPF even more than 8 also reduces the 
production by impairing the penetration of UV rays into the skin. The 
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increased use of sunscreens all over the world for cosmetic purpose and a 
reduced exposure to sunrays over the last several decades led to an increased 
dependence on dietary source of vitamin D. 
 
CHEMISTRY AND STRUCTURE OF VITAMIN D: 
Vitamin D is a secosteroid molecule it is not classified as a essential 
nutrient as it is produced in abundant by the skin on exposure to sunlight. It 
function as a hormone in the body to play a key role in the overall 
metabolism of bony skeleton. 
Its structure is similar to that of cholesterol. It differs from cholesterol 
by presence of double bonds between c7 c8 and c 19 and an open ring 
structure. The two forms of vitamin D utilised in the human body D2 and D3 
begin with four intact rings. The body half life of vitamin D3 molecule is 62 
days. This estimate is based on radioactively labelled vitamin D3. During 
synthesis Ultraviolet B (UV-B 290-310nm) breaks the B ring of both 
compounds by cleaving the bond between C-9 and C-10 of B ring followed 
which a formation of double bond between C-10 and C-10. 
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FIG.7 STRUCTURE OF VITAMIN D 
FOOD SOURCE: 
Food fortification is a common sources of vitamin D [65,66] 
Somecereals may be fortified with vitamin D. There are only a few 
commonly consumed foods that are good sources of vitamin D [65]. Cod 
liver oil, fish, egg yolk, cereals, yogurts, fortified orange juice, mushroom, 
soya, liver and beef are some of the major food sources of vitamin D. The 
plant sources of contains vitamin D2 and the animal source contain Vitamin 
D3. Cod liver oil contains the maximum amount about 1360 IU per serving. 
Most of the non vegetarian food contains the vitamin D. 
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FIG.8 SOURCES OF VITAMIN D 
SYNTHESIS: 
Vitamin D either synthesized from the skin or absorbed from intestine 
enters into the circulation, bound to vitamin D–binding protein (DBP). DBP 
is an α-globulin synthesized in the liver. Ergosterol occurs in plants and 
invertebrate animals and 7 dehydrocholesterol  occurs in vertebrate animal. 
Ergosterol differs from 7 dehydro cholesterol only in its side chain which is 
unsaturated and contains an extra methyl group. Vitamin D is generated from 
the pro vitamin, Dehydrocholesterol by the action of sunlight. Ultraviolet B 
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(UV-B 290-310nm) breaks the B ring of both compounds by cleaving the 
bond between C-9 and C-10 of B ring followed which a formation of double 
bond between C-10 and C-10. In plants ergocalciferol (vitamin D2) is formed 
and in animals cholecalciferol (vitamin D3) is formed from sunlight. 
 Dietary vitamin D2 or D3 observed from the gut in micelles and 
transported into the lymphatics after incorporation into chylomicrons and 
then enters into systemic circulation where it is bound to vitamin D binding 
protein (glycoprotein).vitamin D 3 formed from 7 dehydro cholesterol also 
enters into the blood and it is also bound to vitamin D binding protein. This 
complex of   Vitamin D is hydroxylated in the liver to 25(OH)D by 
cytochrome P450–like enzymes in the mitochondria and microsomes. This 
hydroxylase step in liver is not tightly regulated. 25(OH)D is the major 
circulating form.   
 Vitamin D is stored as 25(OH)D. 88% of 25(OH)D is bound to the 
vitamin D–binding protein  and circulates in the body. 0.03% is in free form 
and remaining 25(OH)D circulates in the body along with albumin. The  
half-life of 25(OH)D is approximately 2 -3weeks. It is shortened dramatically 
if Vitamin D–binding protein levels are decreased, as in nephrotic syndrome 
where there is urinary loss of albumin. Second hydroxylation takes place in 
the proximal tubular cells by the enzyme 1, 25, hydroxylase which converts 
25(OH) D to 1, 25, (OH)2 D and enters into circulation which has a half life 
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of 4 hours and becomes active on binding to VDR. Thus calcitriol, an active 
but unstable 1, 25 dihydroxy Vitamin D [1, 25(OH)2-D] cholecalciferol 
(Calcitriol) synthesised. 
 
FIG.9 SYNTHESIS AND FUNCTION OF VITAMIN D 
 
Thus physiological action of vitamin D on bone and other organ 
system occurs through calcitriol which is the active form of vitamin D. The 
storage form was 25 Hydroxycholecalciferol. 
 
 SYNTHESIS OF VITAMIN D
 
 
 
 
 
 
 
 
 
 
REGULATION OF VITAMIN D SYNTHESIS:
 The ingested vitamin D which is converted into 25(OH) D3 in the liver 
is regulated. The level of 25(OH) D3 reflects the quantity of Vitamin D 
generated in the skin or in the dietary intake.
synthesis of metabolically active vitamin D is rom 1, alpha hydroxylase 
enzyme in the kidney. 
hormone. Low phosphate level is an i
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FIG 10 SYNTHESIS OF VITAMIN D 
 
 In contrast, 
1-alpha-hydroxylase is induced by the parathyroid 
nducer of 1, alpha hydroxylase enzyme
the control of 
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[67].Parathyroid Hormone by acting on a kidney tubular membrane receptor 
reduces the phosphate (as well as HCO3-) reabsorption from PCT. 
Parathyroid hormone also increase the ca+ uptake from DCT and induces the 
conversion of 25(OH) Vitamin D3 to 1,25 (OH) Vitamin D3 and thus 
increases the calcium absorption from G.I tract. 
 
 
FORMS OF VITAMIN D: 
Although 5 forms of vitamin D are known (D1 – D5) D2 and D3 are 
the most studied form. The two major forms are vitamin D2 or ergocalciferal 
and vitamin D3 or cholecalciferal. Vitamin D without subscript refers to 
either D2 or D3 or both. These are knowm collectively as calciferol. Many 
research made on the significant function of vitamin D5. Some recent study 
shows that it has aanti tumour effect.D2 synthesised from plant source and 
D3 from the animal source. The table illustrate the forms of vitamin D   
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FORMS OF VITAMIN D 
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PHYSIOLOGICAL ACTIONS OF VITAMIN D: 
Intestines: 
In the intestine calcitriol, active form of vitamin D stimulates the 
calcium and phosphate absorption and hence increases the level of blood 
calcium and phosphorous [68]. 
Bones: 
 By inducing ca+ absorption, calcitriol helps for the formation and 
maintenance of healthy bone. Calcitriol also act in concern with a many of 
other minerals, vitamins, and hormones for the promotion of bone 
mineralization [69]. 
Other functions: 
 Research suggests that vitamin D may help to maintain a normal 
arterial resistance thereby maintain blood pressure and also a preventive role 
in myocardial infarction an important complication of hypertension [70,71]. 
Also it has a role in maintenance of healthy immune system and help regulate 
cell growth and differentiation. It turns out that vitamin D receptors are 
present in all cells in the body [72]. Vitamin D helps in regulation of muscle 
strength via various mechanism. Many studies proved that vitamin D has a 
role in glycemic control by decreasing the insulin resistance. Still many 
function of Vitamin D are still in research.  
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Vitamin D plays an important role in many normal body functions, including: 
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It is well accepted fact that Calcitriol is needed for the healthy bone as 
it play a major role in calcium and phosphorus metabolism. Many researches 
showed the expression of Vitamin D receptor in various tissue including 
muscle tissue. etal muscle. Severe vitamin D deficiency leads to rickets in 
childrens and osteomalacia in adults manifest as proximal muscle weakness. 
Histological finding shows atropic changes of skeletal muscle fibres 
especially in Type II muscle. There is contradictory evidence to show the 
contribution of Vitamin D for proximal muscle weakness. Some research 
showed a significant correlation and some doesn’t show significant 
association. A recent study investigated the relation between quadriceps  
muscles trength and  vitamin D levels demonstrates a significant association.  
 
  
 
Apart from Vitamin D well understood 
metabolism, Vitamin 
include endocrine, immunity, cardiovascular
neuromuscular function and is also
radical injury, as well as being an induction
protecting cells from carcinogenesis [73]
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role in bone and calcium 
D also plays a major role in multiple system that 
, neuropsychiatric functions, 
 has a antioxidant property
 of cellular level 
 
 
 against free 
differentiation, 
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PLEOTROPIC ACTIONS OF VITAMIN D: 
Pleotropic concept on Vitamin D begins with two discoveries [74].The 
first is finding the expression of Vitamin DReceptors in many tissues other 
than bone tissue. Vitamin DReceptors are seen in many tissues that include 
cardiac tissue, gastro intestinal tissues, Hepatic tissue, Renal tissue, Lungs, 
Brain tissue, pancreas and many immunology cells. The second is the 
discovery of enzyme Cytochrome P27B1 which is capable of converting 
25,hydroxy vitamin D into 1, 25 hydroxy vitamin D in many tissues 
throughout the body. These shows local autocrine and paracrine role of 
Calcitriol added to its function in endocrine [75]. Thus vitamin D in addition 
to calcium and bone homeostasis also has it role in many autocrine and 
paracrine function. Hence it is mentioned as pleotropic effect of vitamin D. In 
all cells it has a role in cell regulation and proliferation. In immune system it 
has a role in both the innate and adoptive immunity. In pancreas in 
facilitation of beta cells. It also plays some role in renin system. In muscles it 
plays role in muscle strength. These are some of the pleotropic effect of 
Vitamin D. 
  
 
 
MECHANISM OF ACTION:
1,25(OH)2D mediates its biologic effects by binding to VD
member of the nuclear receptor superfamily. This receptor belongs to the 
subfamily of receptors of thyroid 
one isoform has been isolated. The VDR binds to target DNA 
recruit a series of co activators
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hormone, the retinoid and PPAR,
 leading to modification of chromatin and
 
R. VDR is a 
 but only 
resulting to 
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hence approximating the VDR to the basal transcriptional apparatus, ending 
in the induction of target gene expression. VDR is expressed in a wide range 
of cells and tissues. Thus it shows that vitamin D is not only a factor for bone 
and homeostasis also in many ass mentioned above. Many non ionic role of 
Vitamin D and Vitamin D Receptors is now a million dollar research subject 
and is used in prevention and progression of carcinomas, inflammatory 
diseases like Multiple sclerosis, Crohn's disease, Rheumatoid arthritis and 
Diabetes mellitus. 
 
TEST FOR VITAMIN D: 
 Vitamin D status refers to the estimation of the vitamin stored in our 
body. The 25- hydroxyl vitamin D3 is widely acknowledged as the best 
indicator or determinant of the nutritional status of this fat soluble vitamin. 
The 25(OH) D directly relates to the body storage whereas 1,25(OH) Vitamin 
D although active metabolite correlates to the disorder involving vitamin D 
endocrine system. Vitamin D is measured in the serum in 25(OH)D form. 1, 
25 (OH)2 D is the active form and its levels are not reliable because it halflife 
is four hours within body and half hour to one hour outside the body. 
Whereas 25(OH)D present in serum is stable and can be measured for a day, 
if sample is kept in room temperature and 2-4oc for 2-3 weeks and in -20oc 
for a year.  
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25(OH)D levels are measured by variety of means like 
 
HPLC, RIA , EIA, CLIA are widely used currently. But there is no 
gold standard method available for measuring 25(OH) D levels.  
NORMAL SERUM LEVEL AND DEFICIENCY: 
Normal serum Vitamin D(25(OH)D)  has wide range 30-100 ng/ ml. 
Vitamin D deficiency is considered to be present when serum 25(OH)D 
levels are <20ng/ml. It is said Vitamin D insufficiency if the levels are 
between 20-30ng/ml and called sufficient if the levels are >30ng/ml.It has 
been stated that most of the individuals have concentrations above 20 ng/ml 
and do not manifest any symptoms as this range is sufficient to maintain bone 
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health. But other metabolic functions of Vitamin D in active form are 
affected. 
In our country none of the individuals should be Vitamin D deficient as 
we live in a country with plenty of sunshine . But various studies conducted 
have shown Vitamin D deficiency /insufficiency in about 50-90% implying 
Vitamin D deficiency is very common in India. Common in all age groups 
and in both sexes.Several studies conducted in North India also confirmed the 
prevalence to be about78-96%. Similar studies conducted in New Delhi by 
Goswami et al and Marwaha et al, also indicated a high prevalence of 
Vitamin D deficiency with a mean 25(OH)D 3 from 8.7±4.3 to 14±9.3ng/ml. 
 
LEVELS OF VITAMIN D:     
 
 
25(OH)D concentration ng/ml nmol/L 
Vitamin D Deficiency <10 <25 
Insufficiency 10-30 25-75 
Normal 30-100 75-250 
Toxicosis >100 >250 
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In India Vitamin D deficiency is a very common problem due to: 
1. Low intake of Vitamin D and calcium due to food faddism and 
altering food habits [76].  
2. The diet with more fibre content contains phytate and phosphate 
which will decrease the stored Vitamin D and also increase the requirement 
of calcium. 
3. Genetic factors like increased 25,hydroxy D 24, hydroxylase which 
cause degradation of 25 hydroxy Vitamin D to inactive compound [77] 
4. Hereditary factor of Vitamin D binding protein plays a role in the 
treatment response in the form of increased 25, hydroxycholecalciferol.[78] 
 5. With urbanisation, the time spent outdoors have decreased thereby 
reduces the adequate sun exposure. Ultra violet B, which plays a major role 
in Vitamin D synthesis has a short wavelength. Thus the maximum synthesis 
was between 10 A.M to 3P.M due to early scattering, the time where most of 
people were indoor. 
6. Increased pollution also contributes to the restriction of ultraviolet 
rays to produce Vitamin D in the skin [79] 
7. Cultural and traditional actors like Burqa and Pardah usage in 
muslims prevents the exposure to sunlight. 
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8. Ultra violet – B was more screened compare to Ultra violet A by the 
sunscreens. Sun screens with SPF 8 will reduce the synthesis by 95% and 
SPF 15 will reduce the synthesis by 98%. The usage of sunscreens become 
more prevalent nowadays. 
9. Multiparity and unspaced pregnancy can lead to increased need that 
aggravate the Vitamin D deficiency both in mother and fetus. 
10. Vitamin D deficiency is more prevalent in elderly people because 
they stay more in indoors and also have poor dietary intake and they are often 
have at least subclinical deficiency. 
 Vitamin D deficiency in elderly is thought to occur mainly due to 
restricted sunlight exposure, reduced dietary vitamin D intake, and decreased 
capacity of the skin to produce vitamin D.MacLaughlin and Holick et al 
examined the effects of ageing on the capacity of the skin to produce 
previtamin D3 in the skin by comparing young subjects (8 and 18 years old) 
with aged subjects (77 and 82 years old). They showed that ageing decreased 
the capacity less than half of young subjects , suggesting that elderly people 
are potentially at risk for vitamin D insufficiency/deficiency.  
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 RECOMMENDED ALLOWANCES: 
AGE CHILDREN MEN WOMEN PREGNANT 
UPTO 13 200IU    
14 – 18  200IU 200IU 200IU 
19 – 50  200IU 200IU 200IU 
51 – 70  400IU 400IU  
OVER 70  600IU 600IU  
 
Recommended Daily Allowance are 400 IU/day for adults, 1000IU for 
babies upto 2yrs, 500-1000U for older children , and 400-800 IU for pregnant 
women. Requirements for vitamin D increase with ageing. 400 IU for those 
aged 51 to 70, and 600 IU for those over 70 years. These recommendations 
were established by determining the level of Vitamin D that was enough to 
prevent bone demineralization or rickets. The safe tolerable upper intake 
level for Vitamin D is 10,000 IU/day.52 Randomized trials using the 
currently recommended intakes of 400 IU of Vitamin D/day have shown no 
appreciable reduction in fracture risk after 50 yrs. In contrast, trials using 
700–800 IU Vitamin D/day found less fracture incidence. 
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SUPPLEMENT: 
 Supplements of Vitamin D are measured in both micrograms (µg or 
mcg) and International Units (IU). 
 
 
  Vitamin D supplements is of 2 types: 
 
Cholecalciferol supplement cause higher and more constant blood levels 
of 25, hydroxy Vitamin D and it is the supplement of choice compared to 
Vitamin D2 [80] 
SARCOPENIA AND VITAMIN D: 
 In vitamin D deficiency, the decline in strength of the proximal muscle 
is one of the prominent feature clinically. Based the invention of Vitamin D 
receptor in the skeletal muscle and its associated decline with ageing many 
interventional studies made to demonstrate the therapeutic effect of Vitamin 
D. Many large scale studies demonstrate a low Vitamin D level with 
increased decline in muscle strength, performance, postural instability, 
walking speed and balance. 
1 microgram (µg or mcg) is equivalent to 40 IU of vitamin D2 or D3.  
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Many morphological changes in muscle was associated with Vitamin 
D deficiency. For example, patients with osteomalacia with muscle 
dysfunction associated with vitamin D deficiency show degenerative changes 
such as fat infiltration in muscle fibres, opaque fibers, ghostlike necrotic 
muscle fibers, regenerating and fibrosed muscle, enlarged interfibrillar 
spaces, fibrosis, glycogen granules, andatropy of the type II muscle fiber. As 
is the case with vitamin D-deficient patients, it is well known that elderly 
people show aberrant muscle morphology. 
In older individuals, vitamin D deficiency leads to not only impaired 
bone mineralization but also muscular myopathy. Multiple crosssectional 
studies in older people have demonstrated an association between low levels 
of 25(OH)D and loss of muscle strength [82 – 84, 91], sarcopenia [82], 
balance [85,86], functional disability, limitations [83,86,87,91], and falls 
[85,88,89]. Kwon et al. reported that low serum 25(OH)D and albumin may 
be associated with a decrease in the objective physical performance of 
community-based older individuals in Japan [90]. Suzuki et al. reported that 
low serum 25(OH)D may be associated with physical performance and fall 
experience [92]. 
 Vitamin D can exert its effects by genomic and non-genomic 
pathways. Both can be involved in muscle function. Besides the muscle cell 
(type II fibers), vitamin D could also influence neuromuscular action. 
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Evidence for the vitamin D receptor (VDR) in muscle cells and cell lines has 
been found by several investigators with different methods such as mRNA, 
calcium-binding protein, and VDR antibodies [93]. The VDR has been 
shown in muscle cells by immunohistochemistry, and the number of 
receptors decreases with aging [94]. vitamin D could still act on muscle 
through another receptor, through neuromuscular interaction, or through 
serum calcium. The active vitamin D metabolite 1,25(OH)2D stimulates 
differentiation of myoblasts [96]. Furthermore, it stimulates calcium influx, 
phosphate transport, and muscle fiber differentiation. 1,25(OH)2D may also 
bind to a membrane receptor, activating cyclic AMP or arachidonic acid. 
Subsequently, calcium is actively transported into the sarcoplasmic 
reticulum, increasing intracellular calcium, necessary for cross-bridge 
formation, and hence muscle contraction [97]. 
 
INTERVENTIONS IN SARCOPENIA: 
Many study demonstrated an improvement in muscular function  that 
includes strength and performance and also decrease the progression of 
sarcopenia with nutritional supplementation and exercise. Exercising 
programs need to be relevant, effective, safe and realistic for the frail elderly 
population they are targeted towards prevention of disability. Participation in 
 regular exercise programs requires motivation from the individual which may 
be difficult for some older subjects.
PHYSICAL EXERCISE:
 
NUTRITION SUPPLEMENTATION: 
PROTEIN:                                 
Many interventio
in all sarcopenic elderly which shows a significant improvement in ahe 
muscle strength and performance. The effect will be maximal if it is along 
with the exercise program. Cambell et al study shows th
protein requirements to maintain muscle mass and function and the elderly 
have low protein intake so 
in sarcopenic subjects. 
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nal study also suggest the nutritional supplementation 
at elderly have 
  protein intake of 1.0-1.5g/kg/d is recommended 
 
high 
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ESSENTIAL AMINOACID: 
The availability of blood AAs is a potent stimulator of muscle protein 
synthesis. As the extraction of essential amino acid increases with ageing the 
availability of essential amino acid decreases. Studies have proven that 15g 
of essential amino acid increases muscle protein synthesis in both young and 
elderly population. Of EAAs, leucine is the most potent stimulator of muscle 
protein synthesis. 
 
VITAMIN D: 
Bischoff-Ferrari et al. studies shows 800IU vitamin D supplementation 
(2-12 months) improves lower extremity strength and function and balance. 
 The Society for Sarcopenia, Cachexia and Wasting Disease 
published nutritional recommendations for sarcopenia in 2010. This 
recommends a balanced protein intake and energy supplement may be useful 
in preventing and reversing sarcopenia as part of a multimodal therapeutic 
approach 
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SOCIETY OF SARCOPENIA CACHEXIA AND WASTING 
DISORDER RECOMMENDATION FOR SARCOPENIA: 
• 15% to 38% of elderly male and 27% to 41% of elderly female intake 
is lower than the RDA for protein so the supplementation of protein 
and increase in dietary supplementation was recommended. 
 
• It is recommends a protein intake of about 1 to 1.5 g/kg/day. 
 
• It is recommended that a leucine rich diet and supplement should be 
added to the diet. 
66 
 
 
 
 
• Creatine may increase the effects of physical exercises in sarcopenic 
individual. 
 
• 25 hydroxyD3 levels should be evaluatedin all elderly with sarcopenia. 
 
• Vitamin D is recommended in doses needed to increase the levels 
above 100 nmol/L as an adjunctive therapy. 
 
 
  
  
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS  
STUDY CENTRE: 
Rajiv Gandhi Government General Hospital and Madras Medical 
College, Chennai. 
ETHICAL COMMITTEE APPROVAL: 
Ethical committee clearance obtained from Institutional Ethical 
Committee of MADRAS MEDICAL COLLEGE held on 03.06.2014.  
STUDY DESIGN: 
Hospital based observational study. 
PERIOD OF STUDY: 
3 months duration June 2014 to August 2014  
STUDY POPULATION: 
100 patients. 
INCLUSION CRITERIA: 
1. Age above 65 years. 
2. Patient who are giving consent for the participation in the study. 
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EXCLUSION CRITERIA: 
1. Patients with severe osteoarthritis / lower limb fracture / hemiplegia / 
upper limb and lower limb disability 
2. Patient with severe cognitive impairment who cannot understand the 
test instruction or give informed consent. 
3. Patients with diabetes mellitus / chronic kidney disease / COPD / 
Acute Illness. 
4. Patient with severe malnourishment / cachexic / malignancy. 
5. Patient taking vitamin D supplementation. 
 
DETAILS OF THE STUDY: 
 100 Elderly population attending Geriatric medicine outpatient 
department in Rajiv Gandhi Government General Hospital were selected in 
the study as per above mentioned inclusion and exclusion criteria. Relevant 
history about co morbidities was obtained. Anthropometric evaluation was 
done. Muscle mass was evaluated using body composition analyzer. Muscle 
strength was assessed based on hand grip strength using handheld 
Dynamometer. The patient was asked to do for 6 times (3 times in each hand) 
and the greater value was taken as handgrip strength. Muscle performance 
was assessed based on gait speed using 4meter walk test. Out of 100 study 
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subjects, 50 healthy elderly without sarcopeniaselected as control group and 
50 subjects with sarcopenia(based on EWGSOP definition) as cases. The 
Vitamin D level of both the group was assessed by means of serum 25, 
hydroxyl cholecalciferol, a surrogate marker of Vitamin D using 
chemiluminiscence method. 
The vitamin D level of both the group with and without sarcopenia was 
assessed and analysed.  
 
 
 
 
 
 
 
     
 
 
 
 
 
  
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
 
 A total of 100 elderly population of age greater than 65years was 
selected in our study. 50 elderly cases with sarcopenia  based on the muscle 
mass, muscle strength and muscle performance and 50 elderly controls 
without sarcopenia was selected based on the inclusion and exclusion criteria 
as mentioned. In the 100 study population ,50 were male and 50 were female. 
The vitamin D level of both group was analysed and the results are as 
follows. 
 
AGE DISTRIBUTION: 
 
 In our study 67% of population were between 65 – 75 yrs of age and 
33% were more than 75 years of age.The mean age of the subjects in the 
study was 72.99 ± 4.56. 
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AGE DISTRIBUTION IN BOTH GROUP: 
   
In our study 76% were in age group ˂ ˂75 yrs and 24% were 75 yrs in 
the healthy control group. 58% were ˂ ˂75 yrs and 42% were 75 yrs in 
sarcopenic groups.  
67%
33%
0%
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20%
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40%
50%
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80%
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Age Group
<75Yrs
>75Yrs
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The age distribution between the two study groups doesn’t show 
significant difference with p value 0.06(p˂  0.05). 
SEX DISTRIBUTION: 
 
 Our study  included of 100 subjects, out of which 50 were male and 50 
were female. In control group and in sarcopenic group, 50% were male and 
50% were female. 
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COMPARISON OF VITAMIN D LEVEL: 
 In our study the prevalence of vitamin D level in sarcopenic group was 
86% and in healthy group was 78%. 
 
The mean vitamin D in healthy group was 58.69±16.36nmol and in 
sarcopenic group was 41.03±16.75nmol. 
  
Gender
Male
Female
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T-TEST FOR COMPARISON OF NORMAL AND SARCOPENIA 
 
The mean level of Vitamin D [25(OH) D3] shows a significant 
difference with mean difference of 17.66 nmol. 
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The Highest vitamin D level86.44nmol and the lowest value of 
22.13nmol in healthy group.The highest value 80.13nmol and 23.45nmol 
lowest value 23.45nmol in sarcopenic group. 
VITAMIN D AND SARCOPENIA 
 
 
 The mean value in Vitamin D level of the two groups shows a 
significant difference with p = 0.001 using Chi Square test. 
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COMPARISON OF SARCOPENIA AND SEVERE SARCOPENIA: 
The vitamin D level of sarcopenic and severe sarcopenic were 
compared.  
 
          The mean vitamin D level in sarcopenic and severe sarcopenic were 
47.54 ± 20.21nmol and 35.92 ± 11.41 nmol respectively. 
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 The mean difference in vitamin D level of sarcopenic and severe 
sarcopenic was 11.61nmol.UsingChi Square test the mean value show a 
significant difference with p value ˂  0.05 
 
 
 
 
 
 
47.54
35.92
0
10
20
30
40
50
sarcopenia Severe
Comparison of Sarcopenia and Severe 
sarcopenia Vitamin D
sarcopenia
Severe
78 
 
VITAMIN D LEVEL AND SARCOPENIA GROUP  
 
VITAMIN D LEVEL IN MALE AND FEMALE: 
T-Test FOR VITAMIN D FOR SEX: 
 
In our study, the mean vitamin D level of male was51.36 ± 18.66nmol 
and female was 48.37 ± 18.83 nmol. 
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Comparison of male and female vitamin D: 
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The mean difference in Vitamin D level of male and female doesn’t 
show a significant difference with p value ˂  0.05. 
 
VITAMIN D - MALE AND FEMALE 
 
COMPARISON OF VITAMIN D FOR AGE GROUP: 
T-Test FOR VITAMIN D FOR Age group: 
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       The mean Vitamin D value of both age group 65 – 75 yrs and more than 
75 yrs were 53.72 ± 19nmol and 52.04 ± 15.63 nmol respectively. 
 
 
 
The mean difference in vitamin D level in the two age group show no 
significant difference with p value ˂  0.05. 
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PREVALENCE OF VITAMIN D – AGE GROUP 
 
 
PREVALENCE OF VITAMIN D: 
The prevalence of vitamin D in both study group of healthy and 
sarcopenic elderly were 78% and 86% respectively. 
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In our study out of 100 subjects[including both healthy and sarcopenic] 
9 subjects had severe deficiency, 73 had insufficient levels  and 18 had 
normal range Vitamin D level. 
 
NORMAL VITAMIN D: 
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VITAMIN D INSUFFICIENCY: 
 
 The mean Vitamin D level in subjects with insufficiency was  45.64 ± 
12.27 nmol; the highest value  was 71 nmol and lowest value was 25.65 
nmol. 
 
VITAMIN D DEFICIENCY: 
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PREVALENCE OF VITAMIN D GROUPS 
 
    
The mean vitamin D level in deficiency, insufficiency and normal were 
24.02nmol, 45.64nmol, and 79.93nmol respectively.  
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MEAN VITAMIN D LEVEL 
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 VITAMIN D DEFICIENCY AND STAGES OF SARCOPENIA:
 
 In our study 18% 
subjects were without sarcopenia, 33.3% were sarcopenic and 5.6% were 
severe sarcopenic. In the study 
in which 49.3% subjects 
and 30.1% with severe sarcopenia.
        In our study 9% of the study subjects were severely Vitamin D deficient
out of which 33.3% had 
severe sarcopenia. 
 
87 
 had normal vitamin D status in which 61.1% 
group ,73%  had insufficient Vitamin D status 
 were without sarcopenia; 20.5% with sarcopenia 
 
no sarcopenia, 11.1% had sarcopenia and 55.6% 
 
 
, 
had 
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VITAMIN D AND STAGES OF SARCOPENIA 
 
The frequency of occurrence of severe vitamin D deficiency show a 
significant difference comparing with the sarcopenic group and without 
sarcopenic group. 
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LEVELS OF VITAMIN D AND SEX DISTRIBUTION: 
 
     
 In our study, out of 50 male subjects 11 had normal vitamin D status, 
36 had insufficient levels  and 33.3 were deficient. Out of 50 female subjects 
in our study 7 had normal Vitamin D level status37 had insufficient levels 
and 6 were deficient. 
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LEVELS OF VITAMIN D AND SEX DISTRIBUTION 
 
 
 
The vitamin D level in male and female group show no significant 
difference using chi square test statistical analysis. 
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VITAMIN D GROUP AND AGE DISTRIBUTION 
 
VITAMIN D GROUP AND AGE DISTRIBUTION CROSS TABLE: 
Crosstab 
  
 
AGE 
Total Chi square P Value <75 Yrs >75 Yrs 
VITAMIN 
D 
GROUP 
 deficiency Count 5 4 9 0.231 0.89 
  
 % within VITAMIN D 
GROUP 
55.56% 44.44% 100.00% 
insufficiency Count 47 26 73 
  
 % within VITAMIN D 
GROUP 
64.38% 35.62% 100.00% 
NORMAL Count 15 3 18 
    
 % within VITAMIN D 
GROUP 
83.33% 16.67% 100.00% 
Total 
Count 67 33 100 
% within VITAMIN D 
GROUP 
67.00% 33.00% 100.00% 
10% 12%
60%
79%
30%
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0%
20%
40%
60%
80%
100%
120%
<75 yrs >75 Yrs
Gender
normal
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In our study the vitamin D level in the age group <75 years and > 75 
years, show no significant difference with p value ˂ 0.05 using Chi Square 
test of statistical analysis. 
 
VITAMIN D AND HAND GRIP STRENGTH: 
 
The mean hand grip strength in normal study group was 32.62±8.70kg 
and the mean hand grip strength in sarcopenic was 12.44±8.21kg. The mean 
gait speed in normal and sarcopenic individual was 0.89 and 0.69 m/sec. 
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SARCOPENIA AND AGE 
 
 
 
 
Mean age of the subjects without sarcopenia was 71±4.58 and with 
sarcopenia was 74.98±3.55. Mean hand grip strength in subjects without 
sarcopenia was32.62±8.70kg and with sarcopeniawas 12.44±8.21kg. 
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SARCOPENIA AND HAND GRIP 
 
 
 
Average gait speed in subjects without sarcopenia was 0.89±0.08m/sec 
and in subjects with sarcopenia was 0.69±0.19m/sec. 
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SARCOPENIA AND GAIT SPEED  
 
ASSOCIATION BETWEEN VITAMIN D AND HANDGRIP 
STRENGTH: 
 
Hand grip strength and vitamin D level show a significant association 
using pearson correlation with p ˂ 0.0001. 
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ASSOCIATION BETWEEN VITAMIN D AND HANDGRIP 
STRENGTH 
 
 
 
 
      
 
 
  
 
 
 
DISCUSSION 
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DISCUSSION 
Sarcopenia is a complex multifactorial condition that can be treated 
with multimodal approaches. Although there is a large body of epidemiologic 
evidence linking sarcopenia to loss in physical function and morbidity, the 
assessment and management of saropenia are not a routine part of clinical 
practice. This study is a small effort to popularise the consensus definition of 
sarcopenia and its relation with vitamin D level, one of the contributing factor 
of sarcopenia.  
 Our   study consists  of 100 participants  with 50 as a control group 
without srcopenia and 50 as study group with sarcopenia based on EWGSOP 
definition. The prevalence of vitamin D deficiency/insufficiency among the 
control group was 78% and among the study group was 86%. According to a 
study regarding prevalence of osteoporosis in Southern India conducted by 
Harinaryanan et al, the  prevalence of Vitamin D deficiency / insufficiency 
was about 50-90%. In North India,  studies conducted by Goswami et al, 
Arya et al,  the prevalence was about 78-96%.  These studies were conducted 
in healthy elderly and healthy adults . 
 In our study population the prevalence of Vitamin D 
deficiency/insufficiency in male and female was 78% and 86% respectively. 
The male and female were almost equally affected. These  results correspond 
to the study result of  Mizumoto et al [11] 
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Many studies demonstrated Vitamin D level and its association with 
skeletal muscle mass, strength and performance in the form of walking speed, 
balance and swaying [98 - 100].The Third National Health and Nutrition 
Examination Survey (NHANES III) study with 4100 participant showed a 
reduced muscle function in subjects with low vitamin D level. This decline in 
muscle function may be due to atrophied type II fibre in vitamin D deficiency 
[101].performance tends to improve within the reference range of 22.5 to 95 
nmol/L, with the most dramatic improvements occurring in the range of 22.5 
to 40 nmol/L [98]. 
           The Longitudinal Study of Aging Amsterdam (LASA) study also 
demonstrates a negative correlation between muscle performance (Mass and 
Hand grip strength) and Vitamin D level. A more recent longitudinal study, 
the Cardiovascular Health Study also shows similar results [104 - 106] 
           In our study though the prevalence of Vitamin D in both the groups 
doesn’t show significant difference as the prevalence rate in healthy 
population was high, the mean 25,hydroxyl vitamin D3 level (the surrogate 
marker of VitaminD ) in both the control and study group shows significant 
difference. The mean vitamin D3 level of control group without sarcopenia 
was 41.03± 16.75 nmol and that of subject group with sarcopenia was 58.69± 
16.36 nmol and the mean difference in vitamin D level were 17.66nmol with 
significant p value of ˂  0.05 comparing with the The Third National Health 
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and Nutrition Examination Survey NHANESIII and Longitudinal Study of 
Aging Amsterdam LASA study. 
In our study the subject with severe sarcopenia i.e. with decreased 
muscle mass, muscle strength and physical performance has a mean  Vitamin 
D level of 35.92±11.41nmol compared with sarcopeniai.e, with decreased 
muscle mass with decreased muscle strength or physical performance 
47.54±20.21nmol. This level correlates  with NHANES Study.   
The prevalence of severe vitamin D deficiency in study population 
with sarcopenia was 33.3%  compared to prevalence in population without 
sarcopenia of 11.1%..The mean vitamin D level of  study population with 
severe sarcopenia was 35.92±11.41nmol compared to 58.69±16.36 in healthy 
elderly.          . 
           In our study 9% of the study subjects were severely Vitamin D 
deficient, out of which 33.3% with no sarcopenia, 11.1% with sarcopenia and 
55.6% were severe sarcopenic. The frequency of occurrence of severe 
vitamin D deficiency show a significant difference compare to the sarcopenic 
group and without sarcopeniagroup.This statistical results shows that 
sarcopenia even though a multifactorial syndrome has a negative correlation 
with the 25 Hydroxycholecalciferol level. 
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A study by Cambell et al recommends that the elderly have high 
protein requirements to maintain muscle mass and function. The geriatric 
population will have low intake of protein. A protein allowance of 1.0-
1.5g/kg/d is recommended in sarcopenic subjects [109]. 15g Essential amino 
acid stimulates muscle protein synthesis in the young and elderly. Of EAAs, 
Leucine is the most potent stimulator of muscle protein synthesis. The 
Society for Sarcopenia, Cachexia and Wasting Disease published nutritional 
recommends the supplementation of Vitamin D to maintain Vitamin D level 
at 100nmol/L. Our study also shows a positive correlation of muscle 
performance (Handgrip strength) with vitamin D level using pearson’s 
correlation formula. 
           Thus our study demonstrates an association between Vitamin D level 
and Sarcopenia and also with physical performance (Hand Grip strength). 
There is no significant difference between Male/Female and age group more 
than 75 and less than 75 years of age. 
 
 
 
 
 
  
 
 
 
LIMITATIONS 
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LIMITATIONS 
 
1. Duration of the study is only 3 months. 
 
2. The study population includes only 100 subjects. 
 
3. The outcome will be better in interventional and follow up study. 
  
  
 
 
 
CONCLUSION 
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CONCLUSION 
Sarcopenia is a age related decline in muscle mass and performance 
The prevalence rate of vitamin D deficiency 78% in normal elderly and 
86% in sarcopenic elderly. The prevalence shows no significant difference in 
both the study groups. 
 The mean difference in Vitamin D level of sarcopenic and normal 
study groupis 17.66nmol which indicates a significant difference. The mean 
difference in Vitamin D level of sarcopenic and severe sarcopenic is 
11.62nmol which also shows a significant difference. 
The male and female study population show no significant difference 
in their Vitamin D level. There is no significant difference in the Vitamin D 
levels between the age groups less than and more than 75 years. 
The sarcopenic patients with vitamin D deficiency show a significantly 
low hand grip strength. 
Thus sarcopenia, the cornerstone for frailty, and related to many 
adverse outcomes in the geriatric population is a multifactorial syndrome(one 
of the factors is Vitamin D which shows a negative correlation in our study). 
Sarcopenia can be managed with nutritional supplement and exercise 
programme which can improve the quality of life and functional 
independence.   
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ANNEXURES 
 ABBREVIATIONS 
 
ADL   - Activity of daily living. 
COPD  - Chronic obstructive pulmonary disease. 
EWGSOP  - The European Working Group on  
    Sarcopeniain older people. 
DEXA  - Dual energy X ray absorptiometry 
BIA   - Bio impedence analysis 
TBK   - Total body potassium 
PBK   - Partial body potassium 
PEF   - Peak expiratory flow 
SPPB   - Short physical performance battery 
UV RAYS  - Ultra violet rays 
PCT   - Proximal convoluted tubule 
DCT   - Distal convoluted tubule 
PTH   - Para thyroid hormone 
VDR   - Vitamin D receptor 
CLIA   - Chemiluminiscentimmuno assay 
RDA   - Recommended daily allowance 
EAA   - Essential amino acid 
  
PROFORMA 
 
A STUDY ON CORRELATION BETWEEN SARCOPENIA AND  
VITAMIN-D LEVEL IN ELDERLY  
 
NAME  : 
 
AGE   :    SEX:   OP NO.  : 
 
ADDRESS  : 
 
RELEVANT HISTORY: 
 
1. Diabetic Mellitus: 
2. History of fractures: 
3. History of Malignancy: 
4. History of Arthritis: 
5. History of Stroke: 
6. COPD: 
7. Chronic Kidney Disease: 
8. History of Vitamin D supplementation: 
 
MUSCLE MASS %:   HEIGHT :        WEIGHT :               BMI : 
 
SKELETAL MUSCLE INDEX : 
 
4METER GAIT SPEED (inmetre/ seconds) : 
 
HAND GRIP STRENGTH (By hand dynamometer in kg): 
 
TICKWHICHEVER IS APPLICABLE: 
 
• PRESARCOPENIA    
• SARCOPENIA    
• SEVERE SARCOPENIA   
• NO SARCOPENIA    
 
VITAMIN D LEVEL: 
 
  
 
 
 
 
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
 
  

  
   

PATIENT CONSENT FORM 
  
Study Detail : “Correlation between sarcopenia and vitamin D 
level in elderly population” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study. ❏ 
d) I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo complete clinical examination and 
hematological tests.  ❏ 
 
 
Signature / thumb impression   Signature of Investigator 
 
 
Patient’s Name and Address :   Study Investigator’s Name :  
Dr. S.PRABHAGARAN 
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